LSE - Delayed Quote CHF

Roche Holding AG (0QQ6.L)

268.40

+1.60

+(0.60%)

At close: April 17 at 4:41:59 PM GMT+1

Stocks to watch next week: Tesla, Alphabet, Intel, Boeing and Unilever

Earnings preview of key companies reporting next week and what to look out for.

Yahoo Finance UK 15 hours ago

MA

FNCTF

ORANY
Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback

JNJ beats first-quarter estimates for earnings and sales. PFE ends the development of the weight loss pill danuglipron.

Zacks yesterday

PFE

SNY

ROG.SW
Roche Gets Nod for Expanded Use of Columvi in Lymphoma in Europe

The European Commission approves RHHBY's Columvi combo to treat adult patients with diffuse large B-cell lymphoma after initial therapy.

Zacks 4 days ago

ROG.SW
Roche’s Columvi combo gains EC approval for DLBCL

The approval follows a conditional marketing authorisation granted in July 2023.

Pharmaceutical Technology 4 days ago

ROG.SW
European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to MabThera/Rituxan plus chemotherapy1,2DLBCL is an aggressive cancer with a high risk of progression meaning urgent and effective treatments are needed for people who relapse or have refractory diseaseThis Columvi regimen offers a much needed off-the-shelf and fixed-duration treatment option for those ineligible for transplant Basel, 14 April 2025 - Roche

GlobeNewswire 4 days ago

RHHBF

RHHBY

RHHVF
Tempest hits funding block for Phase III liver cancer drug-in-waiting

Tempest Therapeutics is eyeing a strategic partner to continue amezalpat’s development amid ‘unavailable capital markets'.

Pharmaceutical Technology 8 days ago

ROG.SW
Tempest seeks strategic alternatives as cash runs out for Phase 3 trial

Amid a funding drought for startups, the company is looking for a deal that can advance its liver cancer drug.

BioPharma Dive 8 days ago

ROG.SW
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More

PCRX and EWTX are in the spotlight this week following important regulatory and pipeline news.

Zacks 9 days ago

EWTX

PCRX

SRPT
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today

Might the tariff risk for pharmaceutical stocks be less than you think?

Motley Fool 9 days ago

AZN

ROG.SW

LLY
Trending tickers: Apple, Advanced Micro Devices, Ford, BP and AstraZeneca

The latest investor updates on stocks that are trending on Wednesday.

Yahoo Finance UK 9 days ago

DAL

GM

SVNDF
Sarepta and Roche aim to resume paused Elevidys trials following patient death

Sarepta and Roche announced a 16-year-old US patient dosed with the gene therapy died of acute liver failure in March 2025.

Clinical Trials Arena 11 days ago

ROG.SW

GLDAF

SRPT
Roche To Start Phase 3 Study For Alzheimer's Prospect This Year After New Data From Phase 2

Roche Holdings AG (OTC:RHHBY) on Thursday presented new data at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases. Highlights included presentations from the ongoing trontinemab Phase 1b/2a Brainshuttle AD study, which demonstrated dose-dependent rapid amyloid depletion from the brain and the potential of the Elecsys pTau181 plasma test to rule out amyloid pathology. Also Read: Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death Prelimin

Benzinga 14 days ago

ROG.SW
SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy

The EMA pauses all clinical studies of Sarepta and Roche's Elevidys following the reported death of a treated patient

Zacks 14 days ago

SRPT

ROG.SW

CTMX
AD/PD 2025: Roche’s Brainshuttle technology promises next generation of amyloid beta mAbs

Encouraging interim results have supported Roche’s decision to move trontinemab into a pivotal Phase III programme.

Clinical Trials Arena 14 days ago

ROG.SW
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death

In March, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy. The company reported a patient death following treatment with Elevidys, having suffered acute liver failure. Acute liver injury is a known possible side effect of Elevidys and other AAV-mediated gene therapies and is highlighted in the prescribing information. On Wednesday, Sarepta and Roche Holdings AG (

Benzinga 15 days ago

SRPT

ROG.SW
AD/PD 2025: DHTs can detect disease progression in patients with early Parkinson’s

DHTs are poised to help bolster the density of outcome data in clinical trials involving Parkinson’s disease.

Pharmaceutical Technology 15 days ago

ROG.SW

GLDAF
Roche's Higher Dose of Ocrevus Fails to Meet Goal in RMS Study

RHHBY's higher dose of multiple sclerosis drug Ocrevus did not meet its primary goal when compared to the approved 600 mg dose in relapsing multiple sclerosis patients.

Zacks 15 days ago

ROG.SW
Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025

SOUTH SAN FRANCISCO, Calif., April 03, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data were presented at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria. Highlights included presentations from the ongoing trontinemab Phase Ib/IIa Brainshuttle™ AD study demonstrating dose-dependent rapid amyloid depletion from the brain and the potential of the Elecsys® pTau181 plasma test to rule out amylo

Business Wire 15 days ago

RHHBF

RHHBY

RHHVF
Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle™ AD study Data on the Elecsys® pTau181 plasma test demonstrate potential to accurately rule out amyloid pathology, one of the hallmarks of Alzheimer’s diseaseRoche will initiate a Phase III programme for trontinemab later this year based on totality of data Basel, 3 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data were presented at the AD/

GlobeNewswire 15 days ago

RHHBF

RHHBY

RHHVF
IoT can help to reduce the burden of clinical trials on patients

IoT helps to decentralise clinical trials, allowing them to become increasingly patient-centric and diverse while providing pharmaceutical companies with a higher return on investment.

Clinical Trials Arena 15 days ago

ROG.SW

Performance Overview

Return	0QQ6.L	MSCI WORLD (^990100-USD-STRD)
YTD	+2.38%	-6.25%
1-Year	+16.40%	+5.97%
3-Year	-29.98%	+17.67%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Roche Holding AG (0QQ6.L)

Stocks to watch next week: Tesla, Alphabet, Intel, Boeing and Unilever

Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback

Roche Gets Nod for Expanded Use of Columvi in Lymphoma in Europe

Roche’s Columvi combo gains EC approval for DLBCL

European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy

Tempest hits funding block for Phase III liver cancer drug-in-waiting

Tempest seeks strategic alternatives as cash runs out for Phase 3 trial

Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More

Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today

Trending tickers: Apple, Advanced Micro Devices, Ford, BP and AstraZeneca

Sarepta and Roche aim to resume paused Elevidys trials following patient death

Roche To Start Phase 3 Study For Alzheimer's Prospect This Year After New Data From Phase 2

SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy

AD/PD 2025: Roche’s Brainshuttle technology promises next generation of amyloid beta mAbs

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death

AD/PD 2025: DHTs can detect disease progression in patients with early Parkinson’s

Roche's Higher Dose of Ocrevus Fails to Meet Goal in RMS Study

Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025

Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025

IoT can help to reduce the burden of clinical trials on patients

Performance Overview